登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)
Efficacy and Safety of Lobaplatin and Carboplatin as Neoadjuvant Therapy in HER-2 Positive Breast Cancer
ClinicalTrials.gov 上登记的一项乳腺癌开放试验,由山东省肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。
状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月18日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。
研究团队的联系方式见登记记录。本站不转递咨询。
列出这项试验的中国大陆医院 1
登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。
登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心
来源:ClinicalTrials.gov 登记记录 NCT07093931,读取于 2026年11月18日;医院名称与本站医院名单匹配。 名称如何匹配
这项试验的核对清单 8
只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。
展开清单(8 项)收起清单
18 岁 至 70 岁;性别:仅女性
登记记录的入选字段
Histologically confirmed HER2 positive ( human epidermal growth factor receptor 2 [ HER2 ] positive, estrogen receptor [ ER ] and progesterone receptor [ PR ] negative or positive );
入选标准第 4 条
Stage at presentation: T1c N1-2 or T2-4 N0-2;
入选标准第 5 条
Provides tumor tissue specimen to assess tumor programmed death-ligand 1 (PD-L1); .For women of childbearing potential: agreement to use contraceptive methods. Women who are not postmenopausal or have undergone a sterilization procedure must have a negative serum pregnancy test result within 72 hours prior to initiation of study drug.
入选标准第 18 条
patients who received chemotherapy, endocrine therapy, immunotherapy, biotherapy or TACE within 4 weeks before admission
排除标准第 3 条
Has participated in an interventional clinical study with an investigational compound within 4 weeks prior to initiation of study treatment
排除标准第 4 条
Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies .Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
排除标准第 5 条
Major surgical procedure within 4 weeks prior to initiation of study treatment
排除标准第 6 条
Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment
排除标准第 12 条
Has evidence of active tuberculosis within 1year prior to initiation of study treatment
排除标准第 13 条
Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment
排除标准第 17 条
Treatment with systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment
排除标准第 18 条
Neutrophils ≥ 1.5×10\^9/L
入选标准第 7 条
Platelets ≥ 100×10\^9/L
入选标准第 8 条
Hemoglobin ≥ 90g/L
入选标准第 9 条
Total bilirubin≤ 1.5 × the upper limit of normal (ULN)
入选标准第 11 条
ALT and AST ≤ 3 × ULN
入选标准第 12 条
ALP≤ 2.5 × ULN
入选标准第 13 条
BUN and Cr ≤ 1.5 × ULN
入选标准第 14 条
TSH≤ ULN
入选标准第 15 条
at least one measurable lesion according to RECIST 1.1;
入选标准第 6 条
Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study .Has a known history of Human Immunodeficiency Virus (HIV).
排除标准第 9 条
Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial .History of neurological or psychiatric disorders, including epilepsy or dementia.
排除标准第 20 条
勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:日常活动能力。
按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07093931,读取于 2026年11月10日。
登记的入选标准
依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。
入选标准:Inclusion Criteria:
Newly diagnosed breast cancer 18-70 Years, female; life expectancy is not less than 3 months Histologically confirmed HER2 positive ( human epidermal growth factor receptor 2 [ HER2 ] positive, estrogen receptor [ ER ] and progesterone receptor [ PR ] negative or positive ); Stage at presentation: T1c N1-2 or T2-4 N0-2; at least one measurable lesion according to RECIST 1.1; Neutrophils ≥ 1.5×10\^9/L Platelets ≥ 100×10\^9/L Hemoglobin ≥ 90g/L lymphocyte≥0.5×10\^9/L Total bilirubin≤ 1.5 × the upper limit of normal (ULN) ALT and AST ≤ 3 × ULN ALP≤ 2.5 × ULN BUN and Cr ≤ 1.5 × ULN TSH≤ ULN Left ventricular ejection fraction (LVEF) ≥ 50% QTcF ≤ 470 ms Provides tumor tissue specimen to assess tumor programmed death-ligand 1 (PD-L1); .For women of childbearing potential: agreement to use contraceptive methods. Women who are not postmenopausal or have undergone a sterilization procedure must have a negative serum pregnancy test result within 72 hours prior to initiation of study drug.排除标准:Exclusion Criteria:
Stage Ⅳ (metastatic) breast cancer or bilateral breast cancer Inflammatory breast cancer patients who received chemotherapy, endocrine therapy, immunotherapy, biotherapy or TACE within 4 weeks before admission Has participated in an interventional clinical study with an investigational compound within 4 weeks prior to initiation of study treatment Prior treatment with anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4), anti-programmed death-1 (anti-PD-1), and anti-PD-L1 therapeutic antibodies .Has a history of invasive malignancy ≤5 years prior to signing informed consent except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer. Major surgical procedure within 4 weeks prior to initiation of study treatment Active or history of autoimmune disease or immune deficiency diseases except history of autoimmune-related hypothyroidism, controlled Type 1 diabetes mellitus Has a history of (non-infectious) pneumonitis, interstitial lung disease or uncontrollable systematicness diseases Administration of a live attenuated vaccine within 28 days prior to initiation of study treatment or anticipation of need for such a vaccine during the study .Has a known history of Human Immunodeficiency Virus (HIV). Has known active Hepatitis B, Hepatitis C or Autoimmune hepatitis Severe infections within 4 weeks prior to initiation of study treatment, including but not limited to hospitalization for complications of infection, bacteremia, or severe pneumonia Has active infection (CTCAE≥2) needed the treatment of antibiotic within 2 weeks prior to initiation of study treatment Has evidence of active tuberculosis within 1year prior to initiation of study treatment Prior allogeneic stem cell or solid organ transplantation Pre-existing motor or sensory neuropathy of a severity≥grade 2 Has significant cardiovascular disease Treatment with systemic immunostimulatory agents within 4 weeks prior to initiation of study treatment Treatment with systemic immunosuppressive medications within 2 weeks prior to initiation of study treatment Has a known hypersensitivity to the components of the study treatment or other hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins Female patients during pregnancy and lactation, fertile women with positive baseline pregnancy tests or women of childbearing age who are unwilling to take effective contraceptive measures throughout the trial .History of neurological or psychiatric disorders, including epilepsy or dementia. any other situation evaluated by researchers
引自 ClinicalTrials.gov, NCT07093931, 参与标准,读取于 2026年11月10日。
这些信息从哪里来
登记记录
ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07093931,读取于 2026年11月18日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。
疾病与医院
本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义
没有收录的内容
登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。